LYON, FRANCE — The anti-obesity drug semaglutide is associated with significant reductions in the inflammatory marker high-sensitivity C-reactive protein , even in patients who do not lose substantial amounts of weight with the drug, according to data from the
"Weight loss was associated with greater high-sensitivity CRP reduction in both treatment groups," said study presenter Jorge Plutzky, MD, director of Preventive Cardiology at Brigham and Women's Hospital, Boston, Massachusetts, but"with increased high-sensitivity CRP reductions in those receiving semaglutide."
Sattar, who was not involved in the study, said that because drugs like semaglutide lower weight but also have anti-inflammatory effects, the question becomes:"Could the anti-inflammatory effects be part of the mechanisms by which these drugs affect the risk of major adverse cardiovascular events?"The current analysis, however, cannot answer the question, he said."All it tells us is about associations.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »